PMVP PMV Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 10 May 2022 PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights

   • Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors
     

   CRANBURY, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2022, and provided a corporate update.

   "Our priority in 2022 is execution of the ongoing Phase 1/2 trial evaluating PC14586, our investigational first-in-class p53 Y220C reactivator, in patients with solid tumors, as well as continued progress on our pipeline" said David Mack…

   View Full Article
2. 27 April 2022 PMV Pharmaceuticals to Present PC14586 Phase 1 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

   • Oral presentation at ASCO to highlight initial data from ongoing Phase 1 study of PC14586, a first-in-class precision oncology investigational therapy, in patients with advanced solid tumors that have a p53 Y220C mutation
     
     

   CRANBURY, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that initial clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 study evaluating PC14586 have been selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place June 3-7, in Chicago, Illinois.

   Details of …

   View Full Article
3. 01 March 2022 PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

   • Continued progress with Phase 1/2 study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors that have a p53 Y220C mutation
   • Strong cash, cash equivalents and marketable securities of $314.1 million as of December 31, 2021

   CRANBURY, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided corporate highlights.

   "We expect that 2022 will be another productive year for PMV Pharma, following accomplishments…

   View Full Article
4. 28 February 2022 PMV Pharmaceuticals to Participate in the 42nd Annual Cowen Health Care Conference

   CRANBURY, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) --  PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in a panel discussion on lung cancer at the 42nd Annual Cowen Health Care Conference taking place virtually March 7-9, 2022. The company will also be available to meet one-on-one with institutional investors at the conference.
   

   Details on the panel can be found below.

   Cowen's 42nd Annual Health Care Conference

   Date:	Wednesday, March 9, 2022
   Time: Format:	9:10 AM – 10:10 AM EST Corporate Panel Discussion
   Title:	Lung Cancer

   …

   View Full Article
5. 03 February 2022 PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day

   CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will represent PMV Pharmaceuticals in a "Fireside Chat" at the Guggenheim Healthcare Talks 2022 Oncology Day taking place on February 9, 2022. The company will also participate in one-on-one investor meetings at the conference.
   

   Details on the presentation can be found below.

   Guggenheim Healthcare Talks 2022 Oncology Day

   Date:	Wednesday, February 9, 2022
   Time:	10:30 am ET
   Format:	Fireside Chat

   About PMV Pharma

   PMV Pharma is…

   View Full Article